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Innate lymphoid cells (ILC) represent a group of lymphocytes that lack specific antigen receptors and are relatively rare as compared to adaptive lymphocytes. ILCs play important roles in allergic and non-allergic inflammatory diseases due to their location at barrier surfaces within the airways, gut and skin and they respond to cytokines produced by activated cells in their local environment. ILCs contribute to the immune response by the release of cytokines and other mediators, forming a link between innate and adaptive immunity. In recent years, these cells have been extensively characterized and their role in animal models of disease has been investigated. Data to translate the relevance of ILCs in human pathology, and the potential role of ILCs in diagnosis, as biomarkers and/or as future treatment targets are also emerging.
This review, produced by a task force of the Immunology Section of the European Academy of Allergy and Clinical Immunology (EAACI) encompassing clinicians and researchers, highlights the role of ILCs in human allergic and non-allergic diseases in the airways, gastrointestinal tract and skin, with a focus on new insights into clinical implications, therapeutic options and future research opportunities.






Innate lymphoid cells (ILCs) are a recently identified family of effector cells, which are important early regulators of immune responses at barrier surfaces. ILCs are instructed by cytokines and lipid mediators produced by epithelial, stromal and myeloid cells and so contribute in shaping the type and intensity of the immune response by producing cytokines and other mediators, and via cell-cell interactions. 
Three subsets of ILCs have been identified:  group 1 (ILC1s), group 2 (ILC2s), and group 3 ILCs (ILC3s), which can be viewed as innate equivalents of T helper (Th) cell subsets Th1, Th2 and Th17, respectively. Extensive information on the ILC surface markers and cytokine production can be found in recent reviews  ADDIN EN.CITE (1, 2). Beyond this canonical classification, ILCs display plasticity and heterogeneity  ADDIN EN.CITE (3). 

ILC1s
ILC1s include various populations of non-cytotoxic IFN-γ-producing ILC1s and the developmentally distinct cytotoxic natural killer (NK) cells. Here we will focus on the non-NK ILC1s, which can be activated by macrophages, dendritic cell (DC)-derived interleukin (IL)-12 and IL-18.  To date, four distinct ILC1 subsets have been described based on their anatomical location and function (4). In steady state, ILC1s are present at low numbers in the dermis, lung, liver, and the intestine, but increase in number upon exposure to intracellular pathogens to protect against viruses and bacteria. In non-resolving chronic inflammatory Th1-like diseases including Crohn’s disease  ADDIN EN.CITE (5) and chronic pulmonary obstructive disease (COPD), the number of ILC1s remains elevated  ADDIN EN.CITE (6). 

ILC2s 
ILC2s were originally characterized as a critical early source of type 2 cytokines for the expulsion of parasitic worms and can be distinguished from other ILC subtypes by the CRTH2 receptor  ADDIN EN.CITE (7). When stimulated by epithelial cell-derived innate mediators i.e. IL-25, IL-33, thymic stromal lymphopoietin (TSLP), or prostaglandin D2 (PGD2), these cells rapidly expand and secrete large amounts of IL-5, IL-13, and under certain conditions, also IL-4 (2). Presently, the pivotal role of ILC2s in allergic airway inflammation is well established in various murine models. In humans, ILC2s were found in healthy lung parenchyma and bronchoalveolar lavage (BAL) fluid from patients who underwent lung transplantation, in nasal polyps, and at low numbers in peripheral blood  ADDIN EN.CITE (7-9). By production of cytokines and via direct interaction with myeloid and Th2 cells, they promote mucus production, eosinophilia and accumulation of mast cells in allergic diseases  ADDIN EN.CITE (10).

ILC3s
ILC3s represent a heterogeneous group of cells comprising of lymphoid tissue inducer cells (LTi) and two subsets of non-LTi ILC3s that can be distinguished by the expression of the natural cytotoxicity receptor NKp44. NKp44- ILC3s can be found in the blood of healthy individuals, whereas all ILC3s subsets reside in tissues (1). ILC3s produce IL-17A, IL-17F, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF), and/or tumor necrosis factor (TNF)-α in response to IL-1β, IL-23, and aryl hydrocarbon receptor (AhR) ligands  ADDIN EN.CITE (11). Depending on specific tissue-derived signals, ILC3s can promote immunity against pathogens, and/or enhance an immunologically tolerogenic state (2). Evidence is accumulating that ILC3s play a critical role in (chronic) non-allergic inflammatory conditions including psoriasis  ADDIN EN.CITE (12) or inflammatory bowel disease  ADDIN EN.CITE (13). 

2.	ILCs in human disease
ILCs in the airways
Under homeostatic conditions, all three ILC subsets are present in the human lung with ILC2s and ILC3s being the most prevalent  ADDIN EN.CITE (6, 14, 15). In healthy mucosal tissue of the nose also all ILC subsets are present, but ILC3s are the predominant population  ADDIN EN.CITE (6). Airway epithelial cells can actively contribute to local tissue inflammatory responses by detecting and responding to environmental pathogens and potential threats by producing cytokines and chemokines that can activate ILCs  ADDIN EN.CITE (16). Based on murine data, where in the lungs almost all ILCs are of ILC2 origin, studies in human have mostly focused on ILC2s. However, in pulmonary homeostasis and in many Th2-low inflammatory diseases the role of other ILC subsets remains to be elucidated. Upper airway inflammation can be studied in mucosal biopsies or by the removal of nasal polyps. Useful tools to study lower airway inflammation are sputum and BAL samples, although these airway sampling methods may not accurately reflect the tissue state, especially as ILCs are thought to be tissue resident cells  ADDIN EN.CITE (17).

Allergic rhinitis (AR)
AR is characterized by an IgE-mediated response at the nasal mucosa upon exposure to airborne allergens in sensitized individuals  ADDIN EN.CITE (18). In AR, the barrier function is disrupted, which is likely to facilitate allergen passage through the epithelium. Moreover, respiratory viruses can further interfere with the barrier integrity and induce the secretion of cytokines, such as IL-33 and TSLP, that may skew the differentiation of immune cells towards the allergic type 2 response involving ILC2s (19) (Figure 1). Additionally, antigen binding to IgE on mast cells results in rapid degranulation and release of mediators such as cysteinyl leukotrienes (CysLTs) and PGD2, which are activators of ILC2s  ADDIN EN.CITE (20, 21). 
Increased (IL-13-producing) ILC2s were found in the blood of patients with house dust mite allergy  ADDIN EN.CITE (22). Moreover, elevated ILC2 numbers are found in the blood after intranasal allergen challenge of cat-sensitized adults  ADDIN EN.CITE (23) and during the grass pollen season in grass allergic patients and in the nasal fluid upon grass pollen challenge  ADDIN EN.CITE (24). However, allergen-dependent differences have been reported  ADDIN EN.CITE (22, 25). 

Chronic rhinosinusitis (CRS) with and without nasal polyps




Asthma is characterized by a variable and often reversible airway obstruction due to chronic inflammation of the respiratory tract. It is a heterogeneous disease that can be associated with allergy. Like in CRS, asthma phenotypes are often based on the distinction between Th2-high and Th2-low disease asthma (35).
IL-5 and IL-13-containing CD34+ non-T cells, likely representing ILC2s, were found in the sputum of patients with allergic asthma following allergen inhalation  ADDIN EN.CITE (36). The involvement of ILC2s in asthma pathogenesis is also supported by (i) genome-wide association study data showing association of asthma with loci encoding IL-33, IL33 receptor, IL-13 and the transcription factor ROR, which are all essential for ILC2s  ADDIN EN.CITE (37), and by (ii) the finding of increased expression of IL-25, IL-33 and TSLP in lungs and sputum of asthma patients  ADDIN EN.CITE (38-41). Higher numbers of total and IL-5/IL-13-producing ILC2s are detected in sputum of patients with severe eosinophilic asthma versus mild asthma  ADDIN EN.CITE (42) and after allergen challenge  ADDIN EN.CITE (43). In another study, ILC2 and IL-33 levels were elevated in BAL of patients with  asthma and IL-33 correlated with disease severity  ADDIN EN.CITE (44). The proportions of ILC2s were also found to be higher in BAL from children with severe therapy-resistant asthma  ADDIN EN.CITE (45). Increased ILC2s are found in blood of asthma patients and these cells produced more IL-5 and IL-13 in response to IL-25 or IL-33 compared to healthy controls or AR patients  ADDIN EN.CITE (46). Whereas similar peripheral blood ILC2 proportions were found in asthma patients and controls in an earlier study (47), the finding of increased ILC2 numbers in patients with asthma was confirmed by several subsequent reports  ADDIN EN.CITE (42, 48, 49). Taken together, these studies suggest the involvement of ILC2s in specific subgroups of asthma (Figure 1). Recently, it has been shown that ILC2-derived IL-13 disrupts the bronchial integrity of airway epithelial cells in asthma, thereby sustaining the type 2 inflammation in the airways  ADDIN EN.CITE (50).

Th2-low asthma
Different non-allergic factors, such as pathogens, air pollutants, and obesity can exacerbate asthma and contribute to the heterogeneous pattern of asthma (35). Human data are scarce, but in mice IL-17A producing ILC3s were implicated in obesity-induced asthma  ADDIN EN.CITE (51, 52), indicating a possible role for IL-1β  ADDIN EN.CITE (51) as this cytokine can stimulate both ILC2s and ILC3s  ADDIN EN.CITE (6, 53, 54). In a pilot study ,  IL-17A-producing-lineage negative cells in BAL were demonstrated to be  enriched in patients with severe asthma  ADDIN EN.CITE (51). So far, no other studies have been performed analysing ILC subsets in patients with Th2-low asthma.

Chronic obstructive pulmonary disease (COPD)
Even though asthma and COPD share some clinical features, the inflammatory pattern differs (55). COPD is usually characterized by a more pronounced neutrophilic and/or type 1 inflammation. In patients with GOLD stage I and II the ILC profile tended to shift towards IL-17-producing NKp44- ILC3 (14). In a different study, GOLD stage IV patients had significantly more ILC3s and ILC1s, due to the differentiation of ILC2s into ILC1s  ADDIN EN.CITE (6). Elevated ILC1 numbers were also found in peripheral blood of COPD patients, correlating with disease severity and susceptibility to exacerbations (56). Recently, ILC3s were detected in inflammatory aggregates and near blood vessels in lungs of smokers and COPD patients providing insight into the initiation of smoke-induced ectopic pulmonary lymphoid aggregates (Figure 1)  ADDIN EN.CITE (15). 

Viral infections and exacerbations 
Upper respiratory viral infections are the main cause of asthma exacerbations  ADDIN EN.CITE (57). In mouse models, ILC2 activation upon influenza infection, can induce bronchial hyperreactivity as well as restore barrier integrity by amphiregulin production  ADDIN EN.CITE (8, 58). In respiratory syncytial virus (RSV) infections, ILC2s can confer a type 2-cytokine-associated disease  ADDIN EN.CITE (59). In humans, ILC2s have not been described directly in these pathologies. However, IL-33 and IL-25 have been detected in nasal fluids of infants hospitalised with RSV bronchiolitis  ADDIN EN.CITE (59) and in asthmatic subjects following experimental rhinovirus (RV)16-infection  ADDIN EN.CITE (60, 61). The supernatant of RV-infected primary bronchial epithelial cells activates ILC2s in an IL-33-dependent manner  ADDIN EN.CITE (60). In conclusion, circumstantial evidence suggests that ILC2s may be involved in the immune pathophysiology of viral infections and asthma exacerbations. 

Pulmonary fibrosis
Both ILC2s and ILC3s are implicated in fibrosis (62). ILC2s produce IL-5 and IL-13, which contribute to the pathogenesis of fibrosis, but at the same time can produce amphiregulin. Elevated IL-33 and IL-25 levels were found in the lungs of patients with cystic fibrosis (CF) and interstitial pulmonary fibrosis (IPF)  ADDIN EN.CITE (63-65). IL-25 positively correlated with periostin, and elevated numbers of ILC2s were found in the BAL fluid of fibrosis patients  ADDIN EN.CITE (63). IL-13 contributes to the differentiation of macrophages towards a profibrotic phenotype inducing collagen deposition by fibroblasts  ADDIN EN.CITE (63). Also in patients with systemic sclerosis increased ILC2 numbers were reported, which correlated with the presence of pulmonary fibrosis  ADDIN EN.CITE (66).
ILC3s may play a role in the generation and progression of IL-17-mediated fibrosis as IL-17A and IL-1β levels were elevated in sputum, BAL and bronchial epithelium of patients with CF and IPF  ADDIN EN.CITE (67-69). This implies that the IL-1β – ILC3 – IL-17 axis can be an important target in fibrotic diseases (Figure 1). 

Other pulmonary inflammatory diseases
Elevated ILC2 numbers have been described in other eosinophilic lung diseases, such as in the pleural fluid of patients with primary spontaneous pneumothorax  ADDIN EN.CITE (70) and in blood of patients during helminth infections  ADDIN EN.CITE (71, 72). An expansion of CD117+ ILCs (ILC3s and subset of ILC2s) was found in blood of filarial-infected subjects, compared to filarial-uninfected controls  ADDIN EN.CITE (71). ILC2s are diminished in young children infected with Schistosoma haematobium (bilharzia), whereby anti-helminthic treatment resulted in increased TSLP levels and normalization of ILC2 numbers  ADDIN EN.CITE (72). 

ILCs in the skin
ILCs are present in healthy dermis at a relatively high abundance compared to other barrier tissues, which might be partly explained by the expression of the skin homing marker cutaneous leukocyte-associated antigen on circulating ILCs  ADDIN EN.CITE (12). The most prevalent ILC population in human skin is the ILC2  ADDIN EN.CITE (3). As skin ILC2s express high levels of amphiregulin, they are implicated in tissue homeostasis and repair  ADDIN EN.CITE (73). This is supported by increased ILC2 numbers in healing cutaneous wounds  ADDIN EN.CITE (74). IL-17-producing ILC3s were also elevated in the dermis upon wounding  ADDIN EN.CITE (75) and in mice these cells were shown to be crucial for restoring the epithelium (Figure 2). 

Atopic dermatitis (AD)
AD is a common chronic inflammatory skin disorder characterized by eczematous lesions with lichenification of the skin (76). In lesions of AD, increased IL-4 and IL-13 levels as well as accumulation of skin-resident ILC2s were observed as compared to normal skin  ADDIN EN.CITE (73, 77). There are some differences between the studies regarding whether these skin ILC2s preferentially respond to IL-33 or TSLP  ADDIN EN.CITE (12, 73). Several ILC-modulating factors are dysregulated in AD skin. Elevated levels of IL-25, IL-33, TSLP, and PGD2 were reported, but also cell-cell interactions affect the ILC2 response (Figure 2). Keratinocytes express E-cadherin and B7-H6, thereby interacting with the killer-cell lectin like receptor G1 or with the activating receptor NKp30, respectively, on ILC2s  ADDIN EN.CITE (73, 78). These molecules have opposing functions, resulting in suppression or activation of ILC2s. In AD patients, filaggrin mutations cause defects in the skin barrier function and lead to lower E-cadherin expression  ADDIN EN.CITE (73), resulting in elevated IL-1β levels and an accumulation of ILC2s  ADDIN EN.CITE (79). This is further amplified by widespread expression of B7-H6 in AD skin, promoting type 2 cytokine production  ADDIN EN.CITE (78). These two mechanisms lead to persistent activation of ILC2s. Moreover, ILC2s in AD skin reside in close proximity with basophils  ADDIN EN.CITE (80) and mast cells. IL-4 and PGD2 derived from these cells are potent ILC2-recruiting factors and activators  ADDIN EN.CITE (21). 

Psoriasis
Psoriasis is a chronic inflammatory skin disorder characterized by scaly patches resulting from epidermal thickening and infiltration of inflammatory cells (81). The numbers of IL-22-producing ILC3s were increased in both lesional and non-lesional skin (Figure 2) and blood of patients with psoriasis, compared to healthy subjects  ADDIN EN.CITE (12, 82, 83). Additionally, the increased ILC3 numbers in skin lesions correlated with psoriasis severity  ADDIN EN.CITE (12) and ILC3sproduced IL-22 in response to stimulation with IL-1β and IL-23. IL-22 may limit the ongoing inflammation, paralleling its role in epithelial maintenance in the gut. Its overproduction in diseased skin inhibits terminal differentiation of keratinocytes and promotes the epidermal thickening characteristic for psoriasis   ADDIN EN.CITE (12). 

ILCs in the intestines
In steady state (Figure 3A), ILC3s represent the predominant ILC subset within the intestinal lamina propria  ADDIN EN.CITE (5). Furthermore, a distinct intra-epithelial ILC1 subset resides  ADDIN EN.CITE (5, 84). ILC3s, including lymphoid tissue inducer cells and postnatal ILC3s, are essential for the development of lymphoid structures, including Peyer’s patches and isolated lymphoid follicles that emerge from cryptopatches  ADDIN EN.CITE (85). Moreover, ILC3s contribute to the control of the intestinal homeostasis by rapidly responding to environmental cues and interacting with other immune and non-immune cells. For example, ILC3s directly sense diet-derived retinoic acid and AhR-ligands, which in turn instruct these cells to produce IL-22, contributing to the integrity of the epithelial barrier by inducing mucus production, antimicrobial production, and fucosylation. Furthermore, sensing of intestinal commensals by macrophages induces IL-1β which triggers GM-CSF production by ILC3s, which instructs intestinal phagocytes to produce regulatory molecules, such as retinoic acid and IL-10, to expand regulatory T cells, thereby inducing oral tolerance  ADDIN EN.CITE (86, 87).

Inflammatory bowel diseases (IBD)
IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of the intestine with a relapsing and remitting disease course  ADDIN EN.CITE (88). Whereas in homeostasis, the intestinal lamina propria is predominantly populated by an IL-22-producing ILC3 subset, the ILC composition and cytokine profile within the colon and ileum in IBD is markedly altered. CD is thought to involve both type 1 (IFN-γ) and type 3 (IL-17) cytokines, whereas in UC, both type 2 cytokines and IL-17 are predominantly involved  ADDIN EN.CITE (88). In CD, elevated numbers of IL-17-producing ILC3s were observed  ADDIN EN.CITE (89) and the frequency of IFN-γ-producing ILC1s was dramatically enhanced, which inversely correlated with a decrease of IL-22-producing ILC3s compared to controls  ADDIN EN.CITE (5, 13, 54, 84, 90, 91) and potentially interfering with the maintenance of the epithelial barrier, induction of antimicrobial peptides and wound healing  ADDIN EN.CITE (13). The enhanced frequency of IFN-γ-producing ILC1s directly affects the epithelial barrier, amplifying its disruption. Although low in number at steady state, ILC2s acquired an ILC1-like phenotype by the production of IFN-γ next to IL-13 in the gut of patients with CD  ADDIN EN.CITE (92). Overall, ILCs may contribute to intestinal inflammation (Figure 3B) through cytokine production, lymphocyte recruitment, and organization of the inflammatory tissue and may represent a novel tissue-specific target for subtypes of IBD.

Celiac disease and non-celiac gluten hypersensitivity 
Celiac disease is a T cell-mediated enteropathy characterized by the loss of tolerance to dietary gluten resulting in villous atrophy. The pathogenesis is based on induction of gluten-specific inflammatory Th1 cells and targeted killing of intestinal epithelial cells.
Patient data on ILC involvement are scarce, but in refractory celiac disease type II, an expansion of aberrant non-T cell intraepithelial lymphocytes was observed. These cells are heterogeneous and include ILC-like precursor cells that respond to either IL-15 or IL-21, indicating differential cytokine responsiveness in subsets of patients with refractory celiac disease  ADDIN EN.CITE (93). Another study showed that ILCs producing TNF-α and IFN-γ are significantly increased in the inflamed mucosa of patients with celiac disease  ADDIN EN.CITE (94). The rapid production of TNF-α upon ILC activation, suggest a possible role for ILCs in early phases of tissue damage in celiac disease  ADDIN EN.CITE (94). 
In rectal biopsies from wheat-challenged non-celiac wheat sensitivity (NCWS) patients, increased mucosal IFN-γ-producing ILC1 infiltration was found as compared to IBD controls. Approximately 30% of the IFN-γ-producing CD45+ cells consisted of ILC1s. Two weeks after resuming a wheat-free diet, IFN-γ-producing ILC1 cells significantly decreased  ADDIN EN.CITE (95), suggesting their potential role in NCWS pathogenesis. 
ILC2s might well be implicated in eosinophilic esophagitis, but the available data so far is still very limited  ADDIN EN.CITE (96, 97).

3.	Clinical implications
ILCs as a diagnostic tool
Currently, ILCs cannot be used for diagnosis because a well-defined relationship with clinical manifestations and/or therapeutic is missing, blood ILC numbers are low, there is no advantage over measuring eosinophils and the detection of ILC2s is complex and non-standardized. However, the following observations have been reported (summarized in Figure 4A and Table 1): 
o	Peripheral blood ILC2 numbers correlated with clinical symptoms in patients with seasonal AR  ADDIN EN.CITE (25).
o	ILC2s in mucosal biopsies from patients with CRS correlated with tissue and blood eosinophilia and the presence of nasal polyps  ADDIN EN.CITE (28) and negatively correlated with the number of previous sinus surgeries  ADDIN EN.CITE (31).
o	In aspirin-exacerbated respiratory disease nasal ILC2 numbers correlate positively and blood ILC2 numbers negatively with maximum symptom scores  ADDIN EN.CITE (33). 
o	Peripheral blood IL-13-producing ILC2 numbers correlated with asthma control status (49).
o	In peripheral blood of patients with COPD, elevated ILC1 numbers negatively correlated with lung function (56).
o	Increased numbers of ILC2s were found in BAL fluid from fibrosis patients  ADDIN EN.CITE (63). 
o	Increased ILC2 numbers were shown in pleural fluid of patients with primary spontaneous pneumothorax, and in blood from patients with helminth infections  ADDIN EN.CITE (70-72). 
o	In esophagal biopsies of patients with active EoE, ILC2s numbers were increased  ADDIN EN.CITE (97).
o	Increased numbers of ILC2 were found in lesions from patients with AD  ADDIN EN.CITE (73, 77, 79). 
o	Increased ILC3 numbers were detected in psoriatic skin lesions correlating with disease severity  ADDIN EN.CITE (12).
o	In CD, the numbers of ILC3s and ILC1s were increased and the frequency of ILC1s inversely correlated with disease severity  ADDIN EN.CITE (5, 13, 54, 84, 90).
o	Increased infiltration of ILC1s were found in rectal biopsies from wheat-challenged NCWS patients  ADDIN EN.CITE (95). 

Consequences of ILC plasticity in disease
In response to microenvironmental changes, ILCs display plasticity, i.e. one subset is able to transdifferentiate into another, allowing a quick adaptation to environmental changes. A conversion of ILC3s into ILC1s, induced by IL-12, was found within the intestines of CD patients  ADDIN EN.CITE (5, 92). In a similar IL-12-dependent manner, ILC2s are converted into ILC1s within the lungs of patients with severe COPD  ADDIN EN.CITE (6). It is thought that IFN-γ production from ILC1s worsens the disease outcome. ILC1s can be reconverted into ILC3s by activation with IL-1β, IL-23 and retinoic acid, while IL-4 can convert ILC1s into ILC2s. Targeting these processes may interfere with disease progression and severity. 

ILCs as therapeutic targets
Although the therapeutic benefit of selectively targeting ILCs has not been systematically investigated, many ILC-related pathways have been shown to affect pathologies. Therapeutic strategies can include prevention of ILC activation, interference with intracellular signalling pathways, neutralization of effector cytokines or limiting cell trafficking (Figure 4B). To translate in vitro findings of potential drug candidates in in vivo models, humanized mice (mice with a humanized immune system) are an excellent tool to study ILCs  ADDIN EN.CITE (6, 98). In this manner several ILC2-targeting options have already been evaluated  ADDIN EN.CITE (99, 100). 

Potential future targets:
	Cytokines that activate ILCs such as IL-1β (all ILC subtypes), IL-33 (ILC2), IL-23 (ILC3s), or IL-12p35 (ILC1s).
	Cytokines produced by ILCs, such as IL-13, IL-9 and IL-22.
	ILC modulators that promote protective ILC functions, such as the vitamin A metabolite retinoic acid and vitamin D3  ADDIN EN.CITE (101).
	 Cytokines and lipid mediators that limit pathologic ILC functions, such as IL-27, type I interferons and lipoxin A4  ADDIN EN.CITE (47, 102). 
	Molecules critical for migration and recruitment of ILCs, such as α4β7 and MAdCAM-1.
	Cytokines that induce ILC trans-differentiation.

Targeting ILCs in respiratory diseases
 Although targeting ILCs in rhinitis or asthma has not been systematically investigated, (existing) therapeutic options are able to modulate the inflammatory effects of ILCs. 
Currently, corticosteroids represent the first line medication in allergic diseases, although patients with more severe disease often are refractory to corticosteroids. Reduced ILC2 numbers were found in NP from CRS patients treated with systemic corticosteroids  ADDIN EN.CITE (32). Even though this suggests corticosteroid responsiveness, in another study it was shown that ILC2s are less susceptible to corticosteroid inhibition than Th2 cells (49). TSLP was reported to be a key regulator of corticosteroid resistance  ADDIN EN.CITE (103). 
Another treatment option is immunotherapy. Immune tolerance induced following grass pollen immunotherapy was associated with reduction in blood ILC2 numbers and IL-13 producing ILC2s. Reduction in ILC2s was associated with decreased severity of self-reported symptoms  ADDIN EN.CITE (25).
More specific ILC2-modulating therapies can be realized via targeting of the leukotriene and/or eicosanoid pathways. ILC2s express both the CysLT1  ADDIN EN.CITE (20) and the CRTH2 receptor  ADDIN EN.CITE (21). A leukotriene receptor antagonist (montelukast) was shown to inhibit ILC2 activation  ADDIN EN.CITE (104) and showed clinical effectiveness in (corticosteroid-refractory) obese asthmatics (105), although ILC2s were not analyzed. Similarly, a CRTH2 antagonist (OC000459) improved lung function in moderate and severe eosinophilic asthma  ADDIN EN.CITE (106) and reduced symptoms in grass pollen-sensitized patients  ADDIN EN.CITE (107). A combination of CRTH2 and CysLT1-receptor antagonist may provide synergistic blockade of both Th2- and ILC2- inflammatory pathways, and hence may have therapeutic potential in both allergic and non-allergic eosinophilic airway diseases. Clinical studies in appropriate endotypes should provide evidence for this hypothesis. Another eicosanoid, lipoxin A4 (LXA4) functions as an inhibitor of ILC2s (47) and severe asthma patients have a LXA4 deficiency  ADDIN EN.CITE (108), indicating LXA4 supplementation as a treatment option in these patients.
In addition, approaches with monoclonal antibodies (mAb) against IL-5 or its receptor and anti-IL-4 α receptor led to improved disease in patients with severe nasal polyps (CRSwNP)  ADDIN EN.CITE (109, 110) and in severe refractory eosinophilic asthma  ADDIN EN.CITE (111). Treatment with anti-IL-4 α receptor may also target ILC2s in these airway disorders  ADDIN EN.CITE (109, 112). Upstream blocking of IL-25, IL-33 and TSLP could potentially inhibit both the Th2- and ILC2-inflammatory pathways. Therapeutic approaches targeting these cytokines (‘alarmins’) are presently in early stage development. So far, an anti-TSLP showed protection against allergen-induced airway responses in allergic asthma  ADDIN EN.CITE (113). 
The effects of ILC3s in non-allergic asthma may be modified by targeting IL-17. However, an IL-17 receptor antibody did not improve asthma control in poorly controlled moderate to severe asthma, although in a small subgroup, with high bronchodilator reversibility some effect was seen  ADDIN EN.CITE (114). 

Targeting ILCs in skin diseases
Many components of the pathways relevant to ILC2 activation are being explored to target ILC2 in AD, for example CRTH2 antagonism and anti-IL-13 treatment. Anti-IL4Rα seems promising for the management of AD  ADDIN EN.CITE (115). It may be that combination approaches will be required to obtain optimal efficacy, as described above for leukotriene and prostaglandin co-inhibition  ADDIN EN.CITE (104), whereby interventions typically affect pathways beyond ILC2s.
In psoriasis, ILC3s have emerged as important sources of IL-22 and IL-17. The IL-23/IL-17 cytokine axis can be targeted with anti-IL-17A and anti-IL-23p40 which are licensed for therapeutic use, and clinical trials of anti-IL23p19 show significant and prolonged efficacy  ADDIN EN.CITE (116). Further therapeutic aspects of blocking this pathway are being actively investigated.

Targeting ILCs in intestinal diseases
The shift from IL-22 to IL-17-producing cytokines in CD patients led to targeting IL-17 (using secukinumab) in a therapeutic setting. However, clinical trials did not reach their endpoint due to exacerbated disease activity  ADDIN EN.CITE (117). ILC plasticity may be utilized to induce a shift from pathological ILC1s into beneficial ILC3s in IBD patients. Remarkably, previous clinical trials targeting IFN-γ (using fontolizumab)  ADDIN EN.CITE (118) or the p40 subunit of IL-12 (as main IFN-γ inducing cytokine) did not reach clear therapeutic efficacy  ADDIN EN.CITE (119). Furthermore, p40 directed therapy does not specifically target IL-12, as IL-23 shares the same domain. A p35 antibody specific to the IL-12 axis should be further examined. In addition, targeting IL-17 and IL-22 is difficult, as for both cytokines tissue-protective and pro-inflammatory effects have been described. Nevertheless, ILC3s play an important role in maintenance of homeostatic conditions and in disease pathogenesis. Additionally, therapeutic approaches supporting the induction of ILC2 and the IL-33-ILC2-amphiregulin pathway could be beneficial in the treatment of IBD patients  ADDIN EN.CITE (120).

4.	Research needs
There remains a need for further investigation of the role of ILCs in human allergic and non-allergic diseases for better understanding of the pathophysiology and to promote the development of new targeted therapeutic strategies. In many diseases, the numbers or activity of ILCs are altered, but it still needs to be established whether these changes correlate with symptoms and disease severity.
Although, in general, there is consensus on how to classify the different ILC populations, further efforts should be made to uniform protocols regarding the markers to be used to selectively identify each ILC subset and to exclude contaminating cells. A recent report elegantly showed that there is both inter-individual heterogeneity and variation across tissues with respect to the surface marker expression  ADDIN EN.CITE (3). Better instruments/methods to quantify ILC subsets are crucial, because currently available methods can be used in a research setting, but are not suitable in routine clinical practice.  









Allergic rhinitis		 ADDIN EN.CITE (22-25)	
CRS		 ADDIN EN.CITE (6, 9, 28, 29, 31-33)	
Allergic asthma		 ADDIN EN.CITE (36-50, 103)	
Non-allergic asthma			 ADDIN EN.CITE (51)
COPD	 ADDIN EN.CITE (6, 56)		 ADDIN EN.CITE (14, 15)
Viral infections		 ADDIN EN.CITE (59-61)	
CF		 ADDIN EN.CITE (64)	 ADDIN EN.CITE (68, 69)
IPF		 ADDIN EN.CITE (63, 65)	 ADDIN EN.CITE (67)
Primary spontaneous pneumothorax		 ADDIN EN.CITE (70)	
Helminth infections		 ADDIN EN.CITE (71, 72)	 ADDIN EN.CITE (71)
Skin			
Homeostasis		 ADDIN EN.CITE (74)	 ADDIN EN.CITE (75)
AD		 ADDIN EN.CITE (73, 77-80)	
Psoriasis			 ADDIN EN.CITE (12, 82, 83)
Gut			
Homeostasis	 ADDIN EN.CITE (5, 54, 84)		 ADDIN EN.CITE (54, 85) 
EoE		 ADDIN EN.CITE (96, 97)	
IBD	 ADDIN EN.CITE (5, 13, 54, 84, 90, 92) 		 ADDIN EN.CITE (5, 13, 54, 84, 89-91)
Celiac disease	 ADDIN EN.CITE (93, 94)		
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Figures and Table legends
Figure 1: Innate lymphoid cells in airway diseases
In homeostasis, all innate lymphoid cell (ILC) subsets are present in the human lungs. In non-allergic inflammation, IL-1β secreted from (alveolar) macrophages can activate both ILC2s and ILC3s. This leads to the secretion of type 2 cytokines by ILC2s, including IL-13 which is implicated in fibrosis, and IL-17A from ILC3s which recruits monocytes and neutrophils. In response to inhaled allergens, the epithelium produces cytokines, such as IL-33 and TSLP, inducing a type 2 response. Cysteinyl leukotrienes (CysLTs) and prostaglandin D2 (PGD2), secreted by activated mast cells, are activators of ILC2s. Upon activation, ILC2s rapidly expand and secrete large amounts of IL-5, IL-13. ILC2s contribute to the allergic airway inflammation by direct interaction with myeloid and Th2 cells, promoting cytokine and mucus production, eosinophilia and accumulation of mast cells.

Figure 2: Innate lymphoid cells in skin diseases
ILCs are abundant in the dermis and they are implicated in tissue homeostasis and wound repair due to the secretion of amphiregulin and IL-22 by ILC2s and ILC3s, respectively. In psoriasis, the numbers of IL-22 producing ILC3s are elevated. IL-17A, secreted from ILC3s, recruits monocytes and neutrophils. In patients with atopic dermatitis, elevated levels of IL-4 and IL-13 are found in parallel with increased levels of IL-33, TSLP and PGD2. Keratinocytes interact with ILC2s via the B7-H6 - NKp30 axis and the E-cadherin – killer-cell lectin like receptor G1 (KLRG1) interaction, leading to activation or suppression of ILC2s, respectively. 

Figure 3: Innate lymphoid cells in intestinal homeostasis and diseases 
A: ILC3s are important regulators of the homeostasis as they rapidly respond to the local environment by the secretion of IL-22 and granulocyte-macrophage colony-stimulating factor (GM-CSF). IL-22 contributes to the epithelial barrier function and mucus production, while GM-CSF stimulates intestinal macrophages to secrete IL-10 and retinoic acid regulating the expansion of regulatory T cells (Tregs) and the induction of tolerance. ILC3s are also important for the development of lymphoid structures, such as Peyer’s patches and isolated lymphoid follicles.
B: The altered cytokine profile in the intestines of patients with Crohn’s disease (CD) or ulcerative colitis (UC) leads to elevated IL-17-producing ILC3s and IFN-y producing ILC1s in the intestines of CD patients, while IL-17 and type 2 cytokines are elevated in UC patients. In food allergy, the allergic inflammation is characterized by a type 2 response with enhanced levels of IgE, IL-4 and IL-13 and increased numbers of basophils and mast cells. 

Figure 4: Clinical and therapeutic implications of innate lymphoid cells in allergic and inflammatory diseases
A: Summary of the clinical implications of the subtypes of ILCs in allergic and inflammatory diseases of the airways, gut and skin.
B: Overview of potential therapeutic implications for targeting ILCs via effector cytokines or mediators that implicate ILC function.


Supplementary Table 1: Innate lymphoid cells being implicated in disease
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